Movement Alert｜HBM HOLDINGS-B Intraday Decline 5.61% in Regular Trading, Biotechnology Sector Under Pressure

Market Focus10-13

On October 13, HBM HOLDINGS-B declined 5.61% in regular trading, trading at 10.23 HKD/share, with Turnover of 13.96 million HKD.

Within the Biotechnology sector where HBM HOLDINGS-B belongs, the overall sector is weak. Among individual stocks, AKESO down 3.54%, BEONE MEDICINES down 1.70%, INNOVENT BIO down 1.85%, METIS TECHBIO-P down 11.25%, 3SBIO down 1.02%.

HBM Holdings plc is an investment holding company principally engaged in the development of innovative therapies in the fields of tumor immunology and immunological diseases. The company's products mainly include batoclimab (HBM9161), HBM9378, HBM7020, TCE Program, prusobart (HBM4003), and HBM7022. These products are primarily used for the treatment of generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors. The company provides next-generation antibodies and biological solutions through its proprietary antibody technology platforms Harbour Mice, HBICE, HBICA, and a monoclonal B-cell screening platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100215084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-13 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100215084","market":"us","top_or_hot":-1,"title":"Movement Alert｜HBM HOLDINGS-B Intraday Decline 5.61% in Regular Trading, Biotechnology Sector Under Pressure","media":"Market Focus","content":"<p><p>On October 13, HBM HOLDINGS-B declined 5.61% in regular trading, trading at 10.23 HKD/share, with Turnover of 13.96 million HKD.</p><p>Within the Biotechnology sector where HBM HOLDINGS-B belongs, the overall sector is weak. Among individual stocks, AKESO down 3.54%, BEONE MEDICINES down 1.70%, INNOVENT BIO down 1.85%, METIS TECHBIO-P down 11.25%, 3SBIO down 1.02%.</p><p>HBM Holdings plc is an investment holding company principally engaged in the development of innovative therapies in the fields of tumor immunology and immunological diseases. The company's products mainly include batoclimab (HBM9161), HBM9378, HBM7020, TCE Program, prusobart (HBM4003), and HBM7022. These products are primarily used for the treatment of generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors. The company provides next-generation antibodies and biological solutions through its proprietary antibody technology platforms Harbour Mice, HBICE, HBICA, and a monoclonal B-cell screening platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HBM HOLDINGS-B Intraday Decline 5.61% in Regular Trading, Biotechnology Sector Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HBM HOLDINGS-B Intraday Decline 5.61% in Regular Trading, Biotechnology Sector Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-13 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 13, HBM HOLDINGS-B declined 5.61% in regular trading, trading at 10.23 HKD/share, with Turnover of 13.96 million HKD.</p><p>Within the Biotechnology sector where HBM HOLDINGS-B belongs, the overall sector is weak. Among individual stocks, AKESO down 3.54%, BEONE MEDICINES down 1.70%, INNOVENT BIO down 1.85%, METIS TECHBIO-P down 11.25%, 3SBIO down 1.02%.</p><p>HBM Holdings plc is an investment holding company principally engaged in the development of innovative therapies in the fields of tumor immunology and immunological diseases. The company's products mainly include batoclimab (HBM9161), HBM9378, HBM7020, TCE Program, prusobart (HBM4003), and HBM7022. These products are primarily used for the treatment of generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors. The company provides next-generation antibodies and biological solutions through its proprietary antibody technology platforms Harbour Mice, HBICE, HBICA, and a monoclonal B-cell screening platform.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1100215084","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100215084","pubTimestamp":1791855823,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 13, HBM HOLDINGS-B declined 5.61% in regular trading, trading at 10.23 HKD/share, with Turnover of 13.96 million HKD.Within the Biotechnology sector where HBM HOLDINGS-B belongs, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"走势提醒|HBM HOLDINGS-B日内常规交易下跌5.61%，生物科技板块承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"On October 13, HBM HOLDINGS-B declined 5.61% in regular trading, trading at 10.23 HKD/share, with Turnover of 13.96 million HKD.Within the Biotechnology sector where HBM HOLDINGS-B belongs, the overall sector is weak. Among individual stocks, AKESO down 3.54%, BEONE MEDICINES down 1.70%, INNOVENT BIO down 1.85%, METIS TECHBIO-P down 11.25%, 3SBIO down 1.02%.HBM Holdings plc is an investment holding company principally engaged in the development of innovative therapies in the fields of tumor immunology and immunological diseases. The company's products mainly include batoclimab (HBM9161), HBM9378, HBM7020, TCE Program, prusobart (HBM4003), and HBM7022. These products are primarily used for the treatment of generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors. The company provides next-generation antibodies and biological solutions through its proprietary antibody technology platforms Harbour Mice, HBICE, HBICA, and a monoclonal B-cell screening platform.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100215084","isCrawlerRequest":true}